

4 October 2024

RESPIRI PROGRAMS RECORD SIGNIFICANT REDUCTION IN HEALTHCARE EVENTS EXISTING CLIENT SERVICES SET TO EXPAND BY A\$1.8M+ P.A.

Highlights

- *Respiri's programs show a reduction in re-hospitalisations by 56% and Emergency Room visits by 47%.*
- *Respiri increases Ceras client per patient per month (pppm) revenues from \$49 to \$74 after only 3 months of engagement.*
- *New York Cancer & Blood expands program from 190 to 1,500 patients with recruitment commencing immediately, expected annualised revenues are to increase US\$1.2M (A\$1.8).*
- *Respiri/Ceras partnership expands University of Alabama Hospital program to 2nd hospital system.*

Respiri Limited (ASX:RSH; OTCQB:RSHUF) ("Respiri") is pleased to announce that Company led patient programs have shown a significant reduction in hospitalisations and emergency room visits.

These results have accelerated discussions with new and existing clients, particularly those with risk share/value-based payor/insurer contracts. Respiri is in advanced contractual discussions with numerous new potential clients.

The Company has recently increased the ppm revenues for existing Ceras clients from approximately **US\$49 to US\$74 (+51%)**. This has been done by increasing the number of monthly reimbursed services to patients from approximately **1 to 1.4 after only 3 months**. Improvements in ppm revenues from this existing patient pool is also seen positively by existing clients and potential partner organisations being reviewed/assessed by Respiri.

The meaningful reduction in healthcare events is also likely to lead to reductions in healthcare costs for payors/insurers. Highlighting the significant financial impetus for clients to engage Respiri's services.

Key recorded metrics are:

- **56%** reduction in re-hospitalizations
- **42%** reduction in length of hospital stay.
- **47%** reduction in emergency room visits
- **91%** improvement in medication compliance

Rehospitalization is a major outcome focus for Centers of Medicare and Medicaid (CMS). This parameter is used as a proxy-measure for the effectiveness of hospital patient healthcare provision. Effective discharge and transition to home care is the most cost-effective mode of patient management. CMS imposes significant fines on hospitals for breaching accepted levels of readmission with more than 50%+ of hospitals in the USA being fined. This is a key parameter generating strong interest in the Respiri-led connected services.

The cost of hospitalisation is considerable and a primary driver for clients on risk share/value-based agreement with payors/insurers. **Respiri is in advanced discussions with 4 such major organisations** and the above results have been acknowledged and well received by these clients.

Furthermore, these results have been acknowledged by existing clients and likely to see increased patient enrolment on already contracted programs. New York Cancer and Blood has provided Respiri with an additional 3,000 patients to be enrolled into programs which should see total patients under management to increase from about **190 to 1,500** by the end of CY 2024 and generate an additional **US\$1.2M** in annualised revenues. The group serves patients throughout the New York City area, with 13 locations, 30 providers, and over 12,000 patients. New York Blood and Cancer's foresight and leadership have created a healthcare "community" that has thrived in this more complex healthcare environment.



Ceras Partnership

The Respire/Ceras partnership continues to deliver significant synergies through combining the Respire world class onboarding/clinical team and the Ceras clinical monitoring IT platform and Artificial Intelligence (AI) capabilities. After only 3 months of assuming clinical management of select Ceras clients, Respire has increased the number of monthly reimbursed services from approximately 1 to 1.4, increasing ppm revenues from **US\$49 to US\$74**.

Due to the success of program with University of Alabama Hospital system, the decision was made to expand services to the University's second healthcare system, (DCH Medical Center). These services include Transitional Care Management, Remote Patient Monitoring and Chronic Care Services.

The University of Alabama Hospital has average annual discharges of 10,999 and serves an average 2,914,735 patients every year. DCH Regional Medical Center has 8,281 additional discharges and an additional 1,490,580 patients which represents a significant additional opportunity for Respire connected programs. For context, more than 50% of Americans have at least 2 chronic conditions which could potentially qualify them for Respire led remote patient monitoring programs.

In partnership with the University, these coordinated care services program will be delivered using both onsite and remote staff to appropriate discharged patients to the home. This hybrid service will have staff at the patient bedside prior to discharge to evaluate the patient suitability. This ensures a provider consultation during a discharge evaluation and enrolment into the program.

CEO Comment

Mr Mikel, Respire CEO said, *"Clearly demonstrating that our programs deliver better outcomes for patients resulting in reduced costs for our clients, is another significant step forward for Respire. This is a particularly compelling narrative for our clients engaged in risk share contracts, where optimising investments and reducing costs are key. Additionally, our fee for service clients clearly demonstrate that our programs improve patient's well-being. This continues to build our reputation in the USA which will continue to fuel growth which excite our team."*

For further information, investors and media please contact:

Mr Marjan Mikel
CEO & Managing Director
Respire Limited
P: +61 408 462 873
E: marjan@respire.co

Mr Nicholas Smedley
Executive Chairman
Respire Limited
P: +61 447 074 160
E: nicholas@respire.co

This ASX announcement has been authorised for release by the Board of Directors of Respire Limited.

About Ceras

Ceras is a leading, Boston-based healthcare technology organization specializing in healthcare IT platform development that empower patients on their journey to health independence with real-time monitoring and AI driven insights. Ceras and Respire have been collaborating to bring together their respective expertise to create worldclass solutions for healthcare organization customers, such as Covenant, and will continue to partner to develop and deliver solutions for other clients currently in the Ceras and Respire sales pipelines.



About Respiri Limited – A Revolutionary Remote Healthcare Solutions Provider

Respiri Limited (ASX:RSH, OTCQB:RSHUF) is leading the charge in transforming healthcare delivery in the US. As an innovator in medical devices and MedTech, we combine state-of-the-art technologies with unparalleled clinical expertise. Partnering with healthcare providers and organisations we empower our clients to extend exceptional care into the community, making a real difference to patients' lives.

We're revolutionising healthcare one patient at a time with our disruptive business model, which provides personalised and responsive care. Our cutting-edge R&D sets us apart, offering comprehensive Care Management programs for all major chronic conditions, including our exclusive remote wheeze detection for respiratory disorders.

Through strategic partnerships, we seamlessly integrate our advanced solutions into existing systems and workflows, boosting efficiency and significantly reducing overall healthcare costs. Our data-driven programs and superior clinical expertise position us at the forefront of chronic disease management, ensuring patients' healthcare needs are met consistently and effectively across the continuum of care.

Learn more at www.respiri.co/au

About the wheezo® Medical Device

wheezo®, a world-first FDA-approved Class II medical device, is the sole WheezeRate detector capable of integrating into RPM programs. Developed by Respiri, wheezo® utilises innovative technology to analyse breath sounds for wheeze. The device works with the user-friendly respiri™ app, enabling users to log symptoms and triggers. The wheezo® system creates a comprehensive and individualised patient profile, fostering informed dialogues between patients and physicians. For details on our US offering, visit <https://respiri.co/us> or for [wheezo®](#)

Respiri Limited is headquartered in Melbourne with offices in New York City and Miami.

wheezo® is a registered trademark of Respiri Limited

Forward Looking Statements

Certain statements made in this announcement are forward-looking statements. These forward-looking statements are not historical facts but rather are based on Respiri current expectations, estimates and projections about the industry in which Respiri operates, and its beliefs and assumptions. Words such as "anticipates," "expects," "intends," "plans," "believes," "seeks," "estimates," "guidance" and similar expressions are intended to identify forward looking statements and should be considered an at-risk statement. Such statements are subject to certain risks and uncertainties, particularly those risks or uncertainties inherent in the process of developing technology and in the endeavour of building a business around such products and services. These statements are not guarantees of future performance and are subject to known and unknown risks, uncertainties, and other factors, some of which are beyond the control of Respiri, are difficult to predict and could cause actual results to differ materially from those expressed or forecasted in the forward-looking statements. Respiri cautions shareholders and prospective shareholders not to place undue reliance on these forward-looking statements, which reflect the view of Respiri only as of the date of this release. The forward-looking statements made in this announcement relate only to events as of the date on which the statements are made. Respiri will not undertake any obligation to release publicly any revisions or updates to these forward-looking statements to reflect events, circumstances or unanticipated events occurring after the date of this announcement except as required by law or by any appropriate regulatory authority.